Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced that the three-month, double-blind, placebo-controlled stage of the company’s multicenter Phase 2 Liver ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments Trading Halts

Roth Capital Reiterates Buy Following Conatus Pharmaceuticals (CNAT) Phase II Emricasan Data January 6, 2016 9:26 AM Conatus Pharmaceuticals (CNAT) Resumes Trading; Shares Up 10%January 5, 2016 4:38 PM Conatus Pharmaceuticals (CNAT) to Resume Trading at 4.35 PM ETJanuary 5, 2016 4:11 PM Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical TrialJanuary 5, 2016 4:05 PM Conatus Pharmaceuticals (CNAT) halted, news pendingJanuary 5, 2016 4:01 PM